T lymphocyte activation through the C28 pathway is insensitive to inhibition by the immunosuppressive drug FK-506.
Nanomolar concentrations of the novel immunosuppressive drug FK-506 inhibit the proliferation of human T lymphocytes in vitro induced by mitogenic lectins or by monoclonal antibodies directed against the CD3 or CD2 surface antigens. However, the alternative pathway of T lymphocyte proliferation induced by monoclonal antibodies specific for CD28 together with phorbol esters is unaffected by FK-506.